YolTech Kicks Off First-In-Class In Vivo Gene Editing Trial For TDT
Other Chinese Firms Build Presence In Field
YolTech Therapeutics' first-in-class in vivo gene editing therapy, YOLT-204, in transfusion dependent β-thalassemia recently entered clinical trial. (Shutterstock) 
